FDA clears Qualigen’s IND for trial of solid tumour therapy

The US Food and Drug Administration (FDA) has granted clearance to Qualigen Therapeutics’ investigational new drug (IND) for initiating a Phase I clinical trial of QN-302 to treat advanced or metastatic solid tumours.